119 related articles for article (PubMed ID: 17848357)
1. New drugs: ambrisentan, temsirolimus, and eculizumab.
Hussar DA
J Am Pharm Assoc (2003); 2007; 47(5):664, 666-7, 669-71. PubMed ID: 17848357
[No Abstract] [Full Text] [Related]
2. Eculizumab (Soliris) for paroxysmal nocturnal hemoglobinuria.
Med Lett Drugs Ther; 2007 Sep; 49(1270):79-80. PubMed ID: 17878890
[No Abstract] [Full Text] [Related]
3. Ambrisentan: new drug. Too risky in mildly symptomatic pulmonary hypertension.
Prescrire Int; 2009 Apr; 18(100):54. PubMed ID: 19585715
[TBL] [Abstract][Full Text] [Related]
4. Ambrisentan: a review of its use in pulmonary arterial hypertension.
Rivera-Lebron BN; Risbano MG
Ther Adv Respir Dis; 2017 Jun; 11(6):233-244. PubMed ID: 28425346
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy evaluation of ambrisentan in pulmonary hypertension.
Vizza CD; Fedele F; Pezzuto B; Rubin LJ
Expert Opin Drug Saf; 2012 Nov; 11(6):1003-11. PubMed ID: 22861496
[TBL] [Abstract][Full Text] [Related]
6. Role of ambrisentan in the management of pulmonary hypertension.
Hrometz SL; Shields KM
Ann Pharmacother; 2008 Nov; 42(11):1653-9. PubMed ID: 18957622
[TBL] [Abstract][Full Text] [Related]
7. Ambrisentan (Letairis) for pulmonary arterial hypertension.
Med Lett Drugs Ther; 2007 Oct; 49(1272):87-8. PubMed ID: 17938611
[No Abstract] [Full Text] [Related]
8. Bilateral cotton wool spots after use of an endothelin receptor antagonist.
Khan MA; Pitcher JD; Kawut SM; Ho AC
Ophthalmic Surg Lasers Imaging Retina; 2014; 45(2):156-9. PubMed ID: 24459200
[TBL] [Abstract][Full Text] [Related]
9. Ambrisentan (Letairis) and tadalafil (Adcirca) for pulmonary arterial hypertension.
Med Lett Drugs Ther; 2016 Jan; 58(1485):2-4. PubMed ID: 26714240
[No Abstract] [Full Text] [Related]
10. Ambrisentan, an endothelin receptor type A-selective endothelin receptor antagonist, for the treatment of pulmonary arterial hypertension.
Kingman M; Ruggiero R; Torres F
Expert Opin Pharmacother; 2009 Aug; 10(11):1847-58. PubMed ID: 19601701
[TBL] [Abstract][Full Text] [Related]
11. Extravascular hemolytic attack after eculizumab therapy for paroxysmal nocturnal hemoglobinuria.
Tomita A; Shirasugi Y; Ito T; Tsurumi H; Naoe T
Ann Hematol; 2012 Jul; 91(7):1139-41. PubMed ID: 22080148
[No Abstract] [Full Text] [Related]
12. Long-term safety and efficacy of ambrisentan in Japanese adults with pulmonary arterial hypertension.
Yoshida S; Shirato K; Shimamura R; Iwase T; Aoyagi N; Nakajima H
Curr Med Res Opin; 2012 Jun; 28(6):1069-76. PubMed ID: 22506623
[TBL] [Abstract][Full Text] [Related]
13. An update on the use of ambrisentan in pulmonary arterial hypertension.
D'Alto M
Ther Adv Respir Dis; 2012 Dec; 6(6):331-43. PubMed ID: 22933513
[TBL] [Abstract][Full Text] [Related]
14. Surveillance on The Safety and Efficacy of Ambrisentan (Volibris Tablet 2.5 mg) in Patients with Pulmonary Arterial Hypertension in Real Clinical Practice: Post-marketing Surveillance (Interim Analysis Report).
Takahashi T; Hayata S; Kobayashi A; Onaka Y; Ebihara T; Hara T
Clin Drug Investig; 2018 Mar; 38(3):219-229. PubMed ID: 29282676
[TBL] [Abstract][Full Text] [Related]
15. Ambrisentan.
Frampton JE
Am J Cardiovasc Drugs; 2011 Aug; 11(4):215-26. PubMed ID: 21623643
[TBL] [Abstract][Full Text] [Related]
16. Ambrisentan for sarcoidosis associated pulmonary hypertension.
Judson MA; Highland KB; Kwon S; Donohue JF; Aris R; Craft N; Burt S; Ford HJ
Sarcoidosis Vasc Diffuse Lung Dis; 2011 Oct; 28(2):139-45. PubMed ID: 22117505
[TBL] [Abstract][Full Text] [Related]
17. Effect of ambrisentan on digital ulcers in systemic sclerosis: a case report.
Tomaselli V; D'Ambrosio D; Massarelli L; Roccatello D
Clin Exp Rheumatol; 2014; 32(6 Suppl 86):S-230-1. PubMed ID: 24774305
[No Abstract] [Full Text] [Related]
18. Ambrisentan and its role in the management of pulmonary arterial hypertension.
Macintyre IM; Dhaun N; Goddard J; Webb DJ
Drugs Today (Barc); 2008 Dec; 44(12):875-85. PubMed ID: 19198697
[TBL] [Abstract][Full Text] [Related]
19. Interaction of ambrisentan and phenprocoumon in patients with pulmonary hypertension.
Sommer N; Grimminger J; Ghofrani HA; Tiede H
Pulm Pharmacol Ther; 2014 Jun; 28(1):87-89. PubMed ID: 24650719
[No Abstract] [Full Text] [Related]
20. Ambrisentan-induced severe asymptomatic thrombocytopenia.
Kigitovica D; Šablinskis M; Lejniece S; Lejnieks A; Skride A
Anatol J Cardiol; 2020 Oct; 24(4):285-286. PubMed ID: 33001057
[No Abstract] [Full Text] [Related]
[Next] [New Search]
